10月10日，康弘药业盘中下跌2.02%，截至14:13，报35.92元/股，成交1.06亿元，换手率0.42%，总市值 330.94亿元。 资金流向方面，主力资金净流出117.29万元，特大单买入260.92万元，占比2.47%，卖出201.25万元，占 比1.90%；大单买入1200.69万元，占比11.36%，卖出1377.64万元，占比13.03%。 康弘药业今年以来股价涨89.05%，近5个交易日跌2.79%，近20日跌8.72%，近60日涨23.48%。 截至9月30日，康弘药业股东户数2.40万，较上期减少3.67%；人均流通股28624股，较上期增加3.81%。 2025年1月-6月，康弘药业实现营业收入24.54亿元，同比增长6.95%；归母净利润7.30亿元，同比增长 5.41%。 分红方面，康弘药业A股上市后累计派现20.38亿元。近三年，累计派现10.40亿元。 机构持仓方面，截止2025年6月30日，康弘药业十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股2727.50万股，相比上期减少531.59万股。大成睿享混合A（008269）位居第六大流通股 东，持股1225. ...

10月9日，华大智造盘中上涨2.02%，截至13:34，报70.57元/股，成交1.61亿元，换手率0.56%，总市值 293.94亿元。 资金流向方面，主力资金净流入213.58万元，特大单买入980.85万元，占比6.10%，卖出388.10万元，占 比2.41%；大单买入3111.68万元，占比19.36%，卖出3490.85万元，占比21.72%。 资料显示，深圳华大智造科技股份有限公司位于广东省深圳市盐田区北山工业区综合楼及11栋2楼，成 立日期2016年4月13日，上市日期2022年9月9日，公司主营业务涉及专注于生命科学与生物技术领域,以 仪器设备、试剂耗材等相关产品的研发、生产和销售。 华大智造所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：基因测序、合成生物、 医疗器械、精准医疗、中盘等。 责任编辑：小浪快报 截至6月30日，华大智造股东户数1.35万，较上期增加7.64%；人均流通股15766股，较上期减少7.09%。 2025年1月-6月，华大智造实现营业收入11.14亿元，同比减少7.90%；归母净利润-1.04亿元，同比增长 65.28%。 分红方面，华大智造A股上市 ...

习近平总书记在回信中强调，新起点上，希望你们坚持以新时代中国特色社会主义思想为指导，聚 焦国家重大战略需求，深化教学科研改革，加强基础研究和科技攻关，提高人才培养质量，更好服务经 济社会发展，为建设教育强国科技强国、推进中国式现代化作出新的贡献。 天津大学智能与计算学部电子信息专业学生姚毅强：总书记要求我们更好服务经济社会发展，为建 设教育强国科技强国、推进中国式现代化作出新的贡献。身为电子信息专业的一名硕士研究生，我主要 从事水下图像增强技术的研究工作，我希望能够为国家基础设施维护、经济社会发展贡献自己的力量。 习近平总书记的回信，饱含着对天津大学的关心关爱，对高校勇担立德树人使命、服务强国建设大 局的殷切期望，为天津大学奋进新征程指明了努力方向。 天津大学校长柴立元：我们要紧紧围绕立德树人根本任务，培养更多具有家国情怀、全球视野、创 新精神、实践能力并能引领未来的卓越人才；我们要发挥基础研究主力军、重大科技突破策源地作用， 推动实现高水平科技自立自强。 中国科学院院士、天津大学合成生物与生物制造学院院长元英进：总书记要求我们聚焦国家重大战 略需求，为我们下一步建设高水平研究型大学指明了方向。我们将聚焦关键 ...

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. (Huaheng Bio) is facing a "revenue growth without profit" dilemma, with its market value having dropped by 57% from its peak [2][7]. Company Overview - Established in 2005, Huaheng Bio focuses on synthetic biology technology, primarily engaged in the research, production, and sales of amino acids, vitamins, and bio-based new material monomers, applicable in personal care, functional foods, and nutrition [5]. - The company was listed on the New Third Board in August 2014 and delisted in February 2018. It subsequently went public on the Shanghai Stock Exchange's Sci-Tech Innovation Board in April 2021, raising 625 million yuan at an initial price of 23.16 yuan per share [6]. Financial Performance - Revenue has shown consistent growth, reaching 14.19 billion yuan in 2022, 19.38 billion yuan in 2023, and 21.78 billion yuan in 2024, with a compound annual growth rate of 31.67% over the first three years [9]. - The company reported a net profit of 4.49 billion yuan in 2023, but this plummeted by 57.8% to 1.9 billion yuan in 2024, with a further decline of 23.26% to 1.15 billion yuan in the first half of 2025 [10]. Cost and Profitability Issues - The decline in net profit is attributed to rising costs, with sales costs increasing by 41.7% in 2024 compared to 2023, alongside heightened competition and increased operational expenses [10]. - The gross profit margin has decreased from 38.7% to 24.8% during the reporting period, with a further drop to 23.5% in the first half of 2025 [11]. Market Position - Amino acid products are the primary revenue source, accounting for 69.3% to 82.2% of total revenue during the reporting period [12]. - Huaheng Bio holds the leading global market share in the L-alanine and L-valine segments, despite being approximately one-third the size of its competitor, Kasei Bio, which reported revenues of 29.58 billion yuan in 2024 [12].

Core Viewpoint - Kanghong Pharmaceutical has shown significant stock performance with a year-to-date increase of 95.79%, despite a recent decline over the past 20 days [1][2]. Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported a revenue of 2.454 billion yuan, representing a year-on-year growth of 6.95%, and a net profit attributable to shareholders of 730 million yuan, up 5.41% year-on-year [2]. Stock Market Activity - As of September 30, the stock price of Kanghong Pharmaceutical was 37.20 yuan per share, with a market capitalization of 34.273 billion yuan. The stock experienced a trading volume of 163 million yuan and a turnover rate of 0.65% [1]. - The stock has seen a net outflow of 1.1269 million yuan from major funds, with significant buying and selling activity from large orders [1]. Shareholder Information - As of September 19, the number of shareholders for Kanghong Pharmaceutical increased to 24,900, with an average of 27,573 circulating shares per person, a decrease of 0.74% [2]. - The company has distributed a total of 2.038 billion yuan in dividends since its A-share listing, with 1.04 billion yuan distributed in the last three years [3]. Shareholding Structure - As of June 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited and several mutual funds, with notable changes in their holdings [3].

9月30日，科前生物盘中上涨2.00%，截至13:48，报17.83元/股，成交3954.01万元，换手率0.48%，总市 值83.11亿元。 资金流向方面，主力资金净流出300.63万元，特大单买入143.73万元，占比3.64%，卖出293.14万元，占 比7.41%；大单买入384.66万元，占比9.73%，卖出535.88万元，占比13.55%。 科前生物今年以来股价涨28.63%，近5个交易日涨1.54%，近20日跌0.34%，近60日涨11.44%。 资料显示，武汉科前生物股份有限公司位于湖北省武汉市东湖新技术开发区高新二路419号，成立日期 2001年1月11日，上市日期2020年9月22日，公司主营业务涉及兽用生物制品研发、生产、销售及动物防 疫技术服务。主营业务收入构成为：兽用生物制品94.64%，其他4.46%，其他(补充)0.90%。 截至6月30日，科前生物股东户数9484.00，较上期增加19.03%；人均流通股49148股，较上期减少 15.98%。2025年1月-6月，科前生物实现营业收入4.87亿元，同比增长21.67%；归母净利润2.20亿元，同 比增长44.09%。 分红方 ...

Company Overview - Star Lake Technology, established on April 18, 1992, and listed on August 18, 1994, is located in Zhaoqing, Guangdong Province. The company specializes in the research, production, and sales of food additives, feed additives, chemical raw materials, and pharmaceutical intermediates [1]. Financial Performance - For the first half of 2025, Star Lake Technology reported a revenue of 8.16 billion yuan, a year-on-year decrease of 3.85%. However, the net profit attributable to shareholders increased by 65.22% to 836 million yuan [2]. - The company has cumulatively distributed 1.57 billion yuan in dividends since its A-share listing, with 1.26 billion yuan distributed over the past three years [3]. Stock Performance - As of September 30, Star Lake Technology's stock price increased by 2.01% to 7.61 yuan per share, with a total market capitalization of 12.644 billion yuan. The stock has risen by 24.96% year-to-date [1]. - The stock's trading volume on September 30 was 124 million yuan, with a turnover rate of 1.31% [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 7% to 44,800, while the average circulating shares per person increased by 7.53% to 24,754 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third-largest, holding 36.2164 million shares, an increase of 25.2508 million shares from the previous period [3].

近日，东星医疗（301290）发布公告披露，公司拟以现金收购武汉医佳宝生物材料有限公司(简称"武汉 医佳宝")90%股权，此次交易预计将构成重大资产重组。收购完成后，武汉医佳宝将成为东星医疗控股 子公司。目前，交易价格尚未披露。2021年-2024年，东星医疗业绩较为平稳，但2025年上半年营收、 净利润下滑幅度较大。业绩承压下，东星医疗借并购向外拓展，或能通过快速获得的新产品线，为业绩 带来新的增长点。 业绩承压，资金链显紧张态势 东星医疗主营业务为以吻合器为代表，覆盖多品类手术设备和医疗耗材的外科手术医疗器械，是国内较 早成熟应用"不等高钉"技术的吻合器厂商。近年来，随着"带量采购"政策的不断推进，产品终端价格下 降，能否以量换价成为关键。 从业绩层面来看，东星医疗2021年-2024年业绩较为平稳，基本在4.2亿元-4.5亿元之间波动；归母净利 润则在9700万元-1.2亿元之间波动。但扣非净利润却逐年下滑，上述报告期内分别为1.03亿元、9451万 元、6816万元、6646万元。今年上半年，东星医疗的营收同比下滑14.17%至1.83亿元；归母净利润同比 大幅下滑36.47%至3029万元，扣非净利 ...

日前，南京医药（600713）公告，公司与广州白云山医药集团股份有限公司及广州广药二期基金股权投 资合伙企业（有限合伙）签署《战略投资协议》。 自2014年起， AHAPL入股南京医药，成为其第二大股东。期间，南京医药实现了显著增长：营收从 2013年的187亿元提升至2024年的537亿元，以接近翻三倍的速度增长；归母净利润从3900万元增加至 5.7亿元，增幅超过14倍。 业内观察人士指出，这一成绩主要归功于南京医药管理层和控股股东新工集团的持续推动。同时，沃博 联在国际经验、治理与资源方面的支持，对南京医药的发展也起到了积极作用。 从公告和多方报道来看，广药与南药在资本运作、渠道和中医药产业方面存在较强互补。分析人士推 测，双方的合作前景和意愿在一定程度上促成了沃博联将股权转让给广药。这笔交易与沃博联的全球战 略相吻合，使其得以更加专注于零售和医疗健康主业。 沃博联的"加法"逻辑 根据协议，三方将在资本、自有工业品种分销渠道及中医药等领域展开合作。白云山下属的广药二期基 金将通过协议方式受让南京医药第二大股东 Alliance Healthcare Asia Pacific Limited（"AHAPL ...

Company Overview - Dongfulong Technology Group Co., Ltd. is located in Minhang District, Shanghai, established on December 25, 1993, and listed on February 1, 2011 [2] - The company specializes in the research, design, production, sales, and service of medical freeze-dryers and freeze-drying systems [2] Financial Performance - For the first half of 2025, Dongfulong achieved operating revenue of 2.429 billion yuan, a year-on-year increase of 6.01%, while net profit attributable to shareholders decreased by 59.71% to 45.9195 million yuan [2] - The company has cumulatively distributed 1.782 billion yuan in dividends since its A-share listing, with 512 million yuan distributed over the past three years [3] Stock Performance - As of September 29, Dongfulong's stock price decreased by 2.02% to 14.10 yuan per share, with a total market capitalization of 10.798 billion yuan [1] - Year-to-date, the stock price has increased by 7.02%, with a slight increase of 0.14% over the last five trading days, a decrease of 2.96% over the last 20 days, and an increase of 8.05% over the last 60 days [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 2.35% to 32,100, with an average of 17,526 circulating shares per person, a decrease of 2.30% [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 7.3336 million shares, a decrease of 2.1354 million shares from the previous period, while Southern CSI 1000 ETF is a new shareholder with 3.5502 million shares [3] Capital Flow - On September 29, the net outflow of main funds was 8.5515 million yuan, with no large orders bought and 2.5647 million yuan sold, accounting for 3.76% [1]